Skip to content
Search

Latest Stories

AIMP warns of ‘tsunami of further pharmacy closures’

AIMP warns of ‘tsunami of further pharmacy closures’

Fight4Pharmacies campaign launched, calling on the government to invest in community pharmacy.

The Association of Independent Multiple Pharmacies (AIMp) has raised concerns over the mounting pressure faced by general practitioners (GPs) in England due to the loss of community pharmacies.


According to the organisation, more than 400 local chemists have closed in five years, leading to 2.5 million more GP appointments and exacerbating the strain on already stretched GP surgeries.

AIMp CEO Dr Leyla Hannbeck pointed to a combination of “chronic underfunding, medicine supply challenges and a dysfunctional reimbursement system” as the catalyst behind the alarming surge in pharmacy closures.

She warned that if this trend persists, it could trigger a “tsunami of further pharmacy closures” across the country, as quoted by The Mirror.

Additionally, Dr. Leyla highlighted that the sector is grappling with a £1.2 billion funding deficit, resulting in pharmacies “falling into debt” and uncertainty about their sustainability.

According to AIMP, the previous five-year funding agreement (set in 2019 at £2.6 billion annually) failed to consider inflation. Consequently, this has resulted in a year-on-year real-term funding cut, leading to a £1.2 billion shortfall.

On Wednesday, AIMp launched its Fight4Pharmacies campaign, calling on the government to invest in community pharmacy.

‘No funds available to fund community pharmacies’

During a recent meeting with pharmacy minister Andrea Leadsom, Dr Hannbeck and AIMp board member Has Modi discussed the current challenges in the sector and offered solutions on how the community pharmacy network could support the NHS.

They highlighted to the minister that pharmacies could play a vital role in the prevention agenda and management of long-term conditions, but the current funding shortfall has left has left numerous pharmacies grappling to stay afloat.

Additionally, the minister was informed that the sector “is consistently seeing medicines prices go up and pharmacies are left out of pocket because the concessions are not granted on time and the system is flawed.”

However, Leadsom responded that “there are no funds available to fund community pharmacies”.

Referring to reports received by the government indicating that pharmacies like Boots and other large multiples are “making money,” she suggested that independents should also “strive to increase their retail offering and provide more private services.”

AIMp then outlined to the minister that “not all pharmacies can be compared to Boots.” They elaborated that over 90 per cent of the activities in independent pharmacies are NHS activities and many of these chemists are based in “areas of deprivation and health and inequality where the public cannot pay for private services or goods and expect NHS to cover the costs.”

However, the minister acknowledged that the price fluctuations have left contractors out of pocket and that this needs to be addressed on priority.

More For You

Pharmacist Support calls for birthday donations to meet rising demand for mental health services

More and more pharmacy professionals are reaching out for help, said Danielle Hunt.

Pharmacist Support's birthday appeal: Donate to address growing mental health demand

Pharmacist Support – the independent charity dedicated to the pharmacy profession – is celebrating 184 years of service with the launch of a special birthday donations appeal.

On 15 April, the charity is urging individuals and organisations across the sector to support its campaign to raise vital funds to meet the increasing demand for its mental health and wellbeing services.

Keep ReadingShow less
Prostate cancer: At-home saliva test could save NHS £500 million annually

PRS saliva test can identify prostate cancer that was missed by an MRI scan

Photo credit: gettyimages

Prostate cancer: Spit test better than blood test in spotting men at highest risk

A simple at-home spit test could help detect prostate cancer earlier, saving the NHS around £500 million a year, according to new research published in the New England Journal of Medicine.

Funded by the National Institute for Health and Care Research (NIHR), the study found that the DNA-based saliva test was more accurate than the current prostate-specific antigen (PSA) blood test in identifying men at risk of developing prostate cancer.

Keep ReadingShow less
RPS launches innovative new learning resources for members

With RPS Learn, pharmacists can develop a new skill or improve their understanding of practice or a clinical topic.

Gettyimages

RPS launches new learning resources to boost career development for members

The Royal Pharmaceutical Society (RPS) has launched a new online learning platform designed to support the practice, development and career advancement of its members.

The new platform, called RPS Learn, offers a diverse range of bite-size learning content, available on-demand, catering to all levels — from introductory to advanced and specialist —combining new content with RPS's renowned expertise in education and training to achieve excellence for learners.

Keep ReadingShow less
NICE approves AstraZeneca’s twice-a-day tablet ‘capivasertib’ for advanced breast cancer

HR-positive, HER2-negative advanced breast cancer is currently incurable, and treatment aims to slow progression and prolong life

Gettyimages

NICE approves twice-a-day tablet for advanced breast cancer

Every year, thousands of people with hormone receptor (HR)-positive HER2-negative breast cancer could benefit from a new twice-a-day tablet, now set to be funded immediately through the Cancer Drugs Fund.

The National Institute for Health and Care Excellence (NICE) has approved the use of capivasertib (also known as Truqap), in combination with fulvestrant, as an option for around 1,100 adults with HR-positive HER2-negative breast cancer that has certain genetic mutations and has spread.

Keep ReadingShow less
ABPI and government fast-track VPAG scheme review to address high medicine payment rates

The 2025 VPAG payment rate for newer medicines has been set at 22.9 per cent.

Photo credit: gettyimages

Review of 2024 VPAG scheme to be completed by June

The Association of the British Pharmaceutical Industry (ABPI) and the government have agreed to bring forward a planned review of the 2024 Voluntary Scheme for Branded Medicines Pricing, Access, and Growth (VPAG), originally scheduled for autumn 2025.

The review is expected to be completed in June 2025, aligning with the anticipated release of the government’s 10-year NHS Plan and the Life Sciences Sector Plan as part of the broader industry strategy this summer.

Keep ReadingShow less